HOME > February 24, 2026
Daily News
February 24, 2026
- Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
- Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
- Shionogi to Absorb Torii in April 2027
February 24, 2026
- Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
- Sumitomo, Partners Launch Malaria Vaccine Project Targeting Mid-2030s Approval
February 24, 2026
- Oji Takes Stake in LTL Pharma to Tap LLP Expertise
February 24, 2026
- PM Vows Comprehensive Support for 17 Priority Sectors: Policy Speech
February 24, 2026
- Multiple Drug-Drug Interaction Risks under PMDA Review
February 24, 2026
- Hisamitsu Buyout Closed, Drug Maker Set to Go Private in May
February 24, 2026
- Takeda Logs Positive PIII Data for Entyvio in Pediatric UC
February 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
